Moleculin Biotech (MBRX) Hits New 52-Week Low at $1.25

Shares of Moleculin Biotech Inc (NASDAQ:MBRX) reached a new 52-week low during trading on Wednesday . The company traded as low as $1.25 and last traded at $1.25, with a volume of 4699 shares traded. The stock had previously closed at $1.32.

Separately, Roth Capital set a $8.00 target price on shares of Moleculin Biotech and gave the stock a “buy” rating in a research note on Tuesday.

The stock has a market capitalization of $42.98 million, a price-to-earnings ratio of -2.81 and a beta of -0.79.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). Equities analysts expect that Moleculin Biotech Inc will post -0.57 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Moleculin Biotech stock. CIBC World Markets Inc. purchased a new position in shares of Moleculin Biotech Inc (NASDAQ:MBRX) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 64,850 shares of the company’s stock, valued at approximately $117,000. CIBC World Markets Inc. owned about 0.25% of Moleculin Biotech at the end of the most recent quarter. 4.78% of the stock is owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile (NASDAQ:MBRX)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Recommended Story: Growth Stocks

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.

Leave a Reply